Table 1. Patients’ demographics and clinical characteristics according to treatment.
| Total (%) 173 (100.0) |
Surgery alone n (%) 73 (42.2) |
Adjuvant chemotherapy plus surgery n (%) 100 (57.8) |
p | |
|---|---|---|---|---|
|
Age, years
Media (standard deviation) |
60.0 (13.5) |
64.5 (13.7) |
56.8 (12.4) | <0.001 |
| <40 | 13 (7.5) | 4 (5.5) | 9 (9.0) | 0.026 |
| 41–65 | 97 (56.1) | 34 (46.6) | 63 (63.0) | |
| > 65 | 63 (36.4) | 35 (47.9) | 28 (28.0) | |
| Sex | 0.163 | |||
| Women | 77 (44.5) | 37 (50.7) | 40 (40.0) | |
| Men | 96 (55.5) | 36 (49.3) | 60 (60.0) | |
| Neutrophil/lymphocyte ratio | 0.467 | |||
| <5 | 158 (91.3) | 68 (93.2) | 90 (90.0) | |
| ≥5 | 15 (8.7) | 5 (6.8) | 10 (10.0) | |
|
Albumin (g/dL)
Media (standard deviation) |
3.8 (0.6) | 3.7 (0.6) | 3.8 (0.6) | 0.363 |
| <3.5 | 46 (26.7) | 20 (27.8) | 26 (26.0) | 0.795 |
| ≥ 3.5 | 126 (73.3) | 52 (72.2) | 74 (74.0) | |
| Unknown | 1 | |||
| Albumin/globulin | ||||
| <1.5 | 142 (82.6) | 63 (87.5) | 79 (79.0) | 0.147 |
| ≥1.5 | 30 (17.4) | 9 (12.5) | 21 (21.0) | |
| Unknown | 1 | |||
| Site of tumour | 0.169 | |||
| Antrum | 116 (67.0) | 48 (65.7) | 68 (68.0) | |
| Body | 31 (17.9) | 15 (20.6) | 16 (16.0) | |
| Body and antrum | 19 (11.0) | 7 (9.6) | 12 (12.0) | |
| Fundus | 3 (1.7) | 3 (4.1) | 0 | |
| Fundus and body | 3 (1.7) | 0 | 3 (3.0) | |
| Whole gastric | 1 (0.7) | 0 | 1 (1.0) | |
| Lauren classification | 0.450 | |||
| Intestinal | 82 (47.4) | 37 (50.7) | 45 (45.0) | |
| Diffuse | 68 (39.3) | 29 (39.7) | 39 (39.0) | |
| Mixed | 23 (13.3) | 7 (9.6) | 16 (16.0) | |
| OMS classification | 0.892 | |||
| Tubular adenocarcinoma | 72 (41.6) | 31 (42.5) | 41 (41.0) | |
| Mixed adenocarcinoma | 25 (14.5) | 9 (12.3) | 16 (16.0) | |
| Mucinous adenocarcinoma | 8 (4.6) | 4 (5.5) | 4 (4.0) | |
| Poorly cohesive | 68 (39.3) | 29 (39.7) | 39 (39.0) | |
| Lymphovascular invasion | 0.005 | |||
| Present | 146 (84.4) | 55 (75.3) | 91 (91.0) | |
| Absent | 27 (15.6) | 18 (24.7) | 9 (9.0) | |
| Perineural invasion | 0.075 | |||
| Present | 112 (65.9) | 42 (58.3) | 70 (71.4) | |
| Absent | 58 (34.1) | 30 (41.7) | 28 (28.6) | |
| Unknown | 3 | |||
| Differentiation | 0.402 | |||
| Well | 9 (5.2) | 2 (2.7) | 7 (7.0) | |
| Moderate | 61 (35.3) | 28 (38.4) | 33 (33.0) | |
| Poor and undifferentiated | 103 (59.5) | 43 (58.9) | 60 (70.0) | |
| Lymph node ratio | 0.002 | |||
| 0 | 24 (13.9) | 18 (24.7) | 6 (6.0) | |
| 0.1–13 | 67 (38.7) | 28 (38.4) | 39 (39.0) | |
| 13.1–40 | 56 (32.4) | 21 (28.8) | 35 (35.0) | |
| >40 | 26 (15.0) | 6 (8.2) | 20 (20.0) | |
| Tumour stage | 0.839 | |||
| T1–T2 | 13 (7.5) | 6 (8.2) | 7 (7.0) | |
| T3 | 75 (43.4) | 33 (45.2) | 42 (42.0) | |
| T4 | 85 (49.1) | 34 (46.6) | 51 (51.0) | |
| Nodal stage | 0.003 | |||
| N0 | 24 (13.9) | 18 (24.7) | 6 (6.0) | |
| N1 | 37 (21.4) | 18 (24.7) | 19 (19.0) | |
| N2 | 52 (30.1) | 20 (27.4) | 32 (32.0) | |
| N3a | 33 (19.1) | 10 (13.7) | 23 (23.0) | |
| N3b | 27 (15.6) | 7 (9.6) | 20 (20.0) | |
| Pathologic stage | 0.002 | |||
| IIA | 18 (10.2) | 15 (20.5) | 3 (3.0) | |
| IIB | 32 (18.8) | 14 (19.2) | 18 (18.0) | |
| IIIA | 65 (36.9) | 27 (37.0) | 38 (38.0) | |
| IIIB | 30 (17.6) | 10 (13.7) | 20 (20.0) | |
| IIIC | 28 (16.5) | 7 (9.6) | 21 (21.0) | |
Significant p-values (<0.05) are shown in bold